Arvinas Announces CEO, President, and Board Chair Leadership Transition

summarizeSummary

Arvinas, Inc. announced a leadership transition, with Dr. John Houston stepping down as CEO, President, and Board Chair, and Dr. Randy Teel, formerly CBO, appointed as the new CEO and President.

check_boxKey Events

• CEO, President, and Board Chair Resignation

  Dr. John Houston resigned from his roles as President, Chief Executive Officer, and Chairperson of the Board, effective February 12, 2026.

• New CEO and President Appointed

  Dr. Randy Teel, previously the Chief Business Officer, was appointed as the new President, CEO, and a member of the Board, effective February 12, 2026. Dr. Teel has been with Arvinas since 2018, holding various senior leadership positions.

• New Board Chair Appointed

  Dr. Briggs Morrison, currently the lead independent director, was appointed as the new Chair of the Board, effective February 12, 2026.

• Former CEO's Continued Involvement

  Dr. Houston will remain on the Board as a director and transition into a consultancy role until March 1, 2027, receiving a $457,000 bonus equivalent and continued equity vesting.

auto_awesomeAnalysis

Arvinas, Inc. has announced a significant leadership transition, with long-standing CEO, President, and Board Chair Dr. John Houston stepping down from his executive roles. The appointment of Dr. Randy Teel, an internal executive with extensive company experience, as the new President and CEO, along with Dr. Briggs Morrison as the new Board Chair, suggests a planned and orderly succession. While any change at the top introduces some uncertainty, the internal promotions and Dr. Houston's continued presence on the board and in a consulting capacity aim to ensure continuity. Investors will be watching for the new leadership's strategic direction and execution, particularly given the company's position in the life sciences sector.